KRAS is one of the earliest discovered driver genes in cancer, with frequent mutations observed in lung, pancreatic, and colorectal cancers. Mutations in KRAS (such as G12C, G12D) lead to its continuous activation, driving uncontrolled cell proliferation, making it a key therapeutic target. Despite its discovery in the 1980s, KRAS was long considered "undruggable" due to the lack of a suitable binding site. In 2013, researchers discovered that the KRAS G12C mutation forms a "switch-II" pocket that can be targeted by covalent inhibitors, paving the way for KRAS-targeted drug development. Amgen and Mirati developed Sotorasib (Lumakras) and Adagrasib (Krazati), which were approved in 2021 and 2022, marking a new era in KRAS-targeted therapy. As research advances, drug development is expanding to target more challenging KRAS mutations like G12D, combining other therapeutic mechanisms (such as SHP2, EGFR inhibitors, or immunotherapy) to improve efficacy. For example, the novel drug RMC-6236 induces the formation of complexes between CypA and various RAS(ON) mutant proteins, inhibiting tumor growth and offering an innovative treatment approach. The development of KRAS-targeted drugs breaks the "undruggable" barrier, signaling a paradigm shift towards precision therapy. AMbeed offers a range of KRAS inhibitors, especially milestone novel KRAS inhibitors, to meet your research needs.